In recent years, mode of action (MOA) frameworks have been developed through the International Life Sciences Institute Risk Science Institute and the International Programme on Chemical Safety, including an evaluation of the human relevance of the animal MOA data. In the present paper, the MOA for rat liver tumors induced by Metofluthrin is first analyzed through this framework based on data from studies on Metofluthrin and information on related chemicals from the literature. The human relevance of the rat liver carcinogenic response is then discussed based upon the human relevance framework. Two-year treatment with high dose of Metofluthrin produced hepatocellular tumors in both sexes of the Wistar rats. Metofluthrin induced CYP2B (increased smooth endoplasmic reticulum), resulted in increased liver weights which were associated with centrilobular hepatocyte hypertrophy, and induction of increased hepatocellular DNA replications. The above parameters related to the key events in Metofluthrin-induced liver tumors were observed at or below tumorigenic dose levels. Furthermore, CYP2B induction by Metofluthrin was shown to involve activation of the constitutive androstane receptor in rat hepatocytes. Based on the evidence, including a comparison with the results with another chemical, phenobarbital, acting by a similar MOA, it is reasonable to conclude that Metofluthrin will not have any hepatocarcinogenic activity in humans.
In recent years, a mode of action (MOA) frameworks has been developed through the International Life Sciences Institute Risk Science Institute (Cohen et al., 2004; Meek et al., 2003) and the International Programme on Chemical Safety Sonich-Mullin et al., 2001) , including an evaluation of the human relevance of the animal MOA data. In the present review, the MOA for liver tumors induced by Metofluthrin is first analyzed through this framework (Table 1) based on data from studies on Metofluthrin and information on related chemicals from the literature. The human relevance of the rat liver carcinogenic response is then discussed based upon the human relevance framework Cohen et al., 2004; Holsapple et al., 2006; Meek et al., 2003; Sonich-Mullin et al., 2001) .
Metofluthrin (CAS-No. 240494-70-6 ; 2,3,5,6-tetrafluoro-4-methoxymethylbenzyl (EZ)-(1RS,3RS;1RS,3SR)-2,2-dimethyl-3-(prop-1-enyl)cyclopropancarboxylate) is a new type I pyrethroid insecticide for use in pest control (Lucas et al., 2007; Ujihara et al., 2004) . The carcinogenicity of Metofluthrin has been studied in male and female rats and mice in standard bioassays under the guidelines of Good Laboratory Practice. Male and female HanBrl:WIST rats were fed 0 (control), 20, 200, 900, or 1800 ppm Metofluthrin in the diet for 2 years (Deguch et al., in press ). Metofluthrin was not genotoxic in a battery of in vitro and in vivo assays (unpublished data).
The incidence of hepatocellular adenomas and/or carcinomas was significantly increased in male rats given 900 or 1800 ppm Metofluthrin and in female rats given 1800 ppm Metofluthrin (Fig. 1) . The combined incidences of hepatocellular adenomas and carcinomas of 0, 20, 200, 900, and 1800 ppm groups were, respectively, 2, 2, 6, 16, and 24% for males and 2, 6, 2, 10, and 24% for females. Body weight gain was reduced by 11 and 12% in male and female rats, respectively, at the 900 ppm dose level and by 15 and 19% in male and female rats, respectively, at the 1800 ppm dose level. Historical background incidences for combined liver tumors in the laboratory conducting this bioassay were 0-6% for males and 1-12% for females, respectively. Although the high dose level appeared to exceed the maximum tolerated dose (MTD) in females and, to a lesser extent, in males, it was concluded that Metofluthrin has a weak carcinogenic potential in rats based on the hepatocellular tumors.
In contrast, Metofluthrin was not carcinogenic in the liver or any other tissue in male or female CD-1 mice when administered at dietary levels of 100, 1000, and 1750/2500 ppm (unpublished data).
IS THE WEIGHT OF EVIDENCE SUFFICIENT TO ESTABLISH THE MOA IN ANIMALS?
Postulated MOA The MOA of Metofluthrin-induced liver tumors is postulated to involve activation of the constitutive androstane receptor (CAR) which results in a pleiotropic response including the stimulation of cytochrome P450 (CYP) CYP2B isoforms and increased cell proliferation. This MOA is similar to that of other nongenotoxic, liver CYP2B form inducer/CAR activators, such as phenobarbital (Holsapple et al., 2006; Whysner et al., 1996) . In rodents, this series of events exhibits a clear threshold for the induction of hepatocellular tumors (Whysner et al., 1996) . More importantly, substantial epidemiologic data on phenobarbital, with human exposures similar to those that are carcinogenic to rodents, show that it is not a human carcinogen (IARC, 2001; McClain, 1994; Olsen et al., 1989 Olsen et al., , 1995 Whysner et al., 1996) .
Key Events
The key events for Metofluthrin-induced liver tumor formation include induction through CAR of CYP2B isoforms, increased hepatocellular proliferation and eventually liver foci, adenomas and carcinomas. Several parameters were evaluated to test each of these postulated key events ( Table 2) .
Activation of the nuclear CAR. Phenobarbital has been shown to produce liver tumors in rodents by MOA involving activation of CAR (Holsapple et al., 2006) . Indeed, phenobarbital does not produce liver tumors in CAR knockout mice (Yamamoto et al., 2004) . Since a CAR knockout rat has not to date been developed, the role of CAR in the MOA for Metofluthrin CYP2B induction was determined in rat hepatocytes using the recently developed RNA interference (RNAi) technique. The RNAi technique enables sequence-specific gene silencing using short-interfering RNA (siRNA) (Caplen et al., 2001; Elbashir et al., 2001; Fire et al., 1998) . The treatment of rat hepatocytes with CAR-siRNA significantly reduced CAR mRNA in the presence of either phenobarbital or Metofluthrin, resulting in a significant reduction in the magnitude of induction of CYP2B1 mRNA levels by both compounds (Deguch et al., in press ). These findings demonstrate that Metofluthrin and phenobarbital induce CYP2B1 through CAR, both compounds thus having activating effects on CAR in rat hepatocytes (Deguch et al., in press ).
Enzyme induction. CYP2B isoform induction has been shown to be associated with liver tumor formation in rodents for phenobarbital and related compounds (Holsapple et al., 2006; Whysner et al., 1996) and involves activation of nuclear receptors, particularly the CAR (Ueda et al., 2002; Wei et al., 2000; Yamamoto et al., 2004; Yoshinari et al., 2001) . Although the magnitude of induction of CYP2B isoforms in rodent liver is not by itself a predictor of carcinogenic potential, in the rat studies with a series of barbiturates some correlation was observed between the magnitude of CYP2B form induction and tumor promoting activity (Lubet et al., 1989; Rice et al., 1994) . The MOA studies utilized the 200, 900, and 1800 ppm bioassay dose levels and other dose levels including 450 ppm as an additional dose level and 2700 and 3600 ppm as greater than bioassay dose levels (Deguch et al., in press ). This was done for CYP2B1 and CYP2B2 as well as CYP3A1 and CYP3A2 because phenobarbital induces CYP3A as well as CYP2B isoforms in rodents (Whysner et al., 1996; Yamamoto et al., 2004) . CYP2B1/2 mRNA was induced greater than twofold at dose levels of 450 ppm and higher, whereas the mRNA for CYP3A1 was increased at the dose of 900 ppm and higher, and CYP3A2 mRNA was not increased at any of these dose levels (Deguch et al., in press). Similarly, there was an increase in CYP2B protein levels greater than 1.5-fold at dose levels of 900 and higher whereas there was no increase in CYP3A protein levels at any of these doses (Deguch et al., in press ). These findings were also supported by gene expression profiling analysis (Deguch et al., in press). Furthermore, hepatic activities of 7-pentoxyresorufin O-depentylase (CYP2B marker) and testosterone 6b-hydroxylase (CYP3A marker) were also increased in rats treated with Metofluthrin (only samples from the 3600 ppm group in the MOA study were examined) (Deguch et al., in press). Additional evidence that cytochrome P450 induction is occurring at biologically relevant levels is supported by the observation that there was hepatocellular hypertrophy, particularly seen in the centrilobular region of the liver lobule. Further evidence that the degree of cytochrome P450 induction was biologically relevant is the observation of significant increased smooth endoplasmic reticulum (Ghadially, 1997) observed by transmission electron microscopy (Deguch et al., in press ). This is a characteristic finding for phenobarbital-like cytochrome P450 inducers and is related to the expansion of this organelle which contains the cytochrome P450 enzymes. These are characteristic changes of cytochrome P450 inducers, such as phenobarbital and related compounds. Phenobarbital was used as a positive control in all of the studies described here and subsequently in the evaluation of Metofluthrin. Thus, there is both direct and indirect evidence for cytochrome P450 induction by Metofluthrin administration with biologically important consequences.
Cell proliferation. The support of the key event of increased cell proliferation is the observation of increased liver weight, particularly relative weight. Previous studies with phenobarbital in the rat and mouse have demonstrated that the increase in relative liver weight after short-term treatment is due to both hepatocyte hypertrophy and hyperplasia (IARC, 2001; Whysner et al., 1996) . A sensitive measure of cell proliferation is to assess the rate of S-phase activity of the cell cycle using 5-bromo-2#-deoxyuridine (BrdU) incorporation as a marker of DNA synthesis. Increased proliferation was demonstrated by an increased BrdU-labeling index at the higher doses in male and female rats at week 1 (Deguch et al., in press). However, the BrdU-labeling index values returned to control levels when Metofluthrin treatment was continued for 2 weeks (Deguch et al., in press ). Since hepatocyte cell number is increased by 2 weeks as evidenced by increased liver weight (Deguch et al., in press), the actual number of DNA replications remains greater than controls despite the labeling index being similar to controls. Previous studies have (Furukawa et al., 2000; IARC, 2001; Jones and Clarke, 1993; Kolaja et al., 1996; Whysner et al., 1996) . Thus, there is direct and strong evidence in support of the key events of cytochrome P450 enzyme induction and consequent increased cell proliferation. It should be noted that for all of these effects, the response to Metofluthrin was relatively weak in comparison to those usually seen with a strong inducing agent such as phenobarbital, but the tumorigenic effect was also quite weak even at doses in the region of (900 ppm), or in excess (1800 ppm) of the MTD.
Other parameters. It was demonstrated that there is an inhibition of gap junctional intercellular communication in male and female rats at a Metofluthrin dose level of 1800 ppm, but not at 900 ppm (Deguch et al., in press ). This is a characteristic finding for non-DNA-reactive chemicals that produce hepatocellular tumors in rodents, including cytochrome P450 inducers (Neveau et al., 1990; Ruch and Klaunig, 1988) . Oxidative stress has also been implicated as an important factor in the carcinogenesis process in both genotoxic and nongenotoxic mechanisms (Klaunig and Kamendulis, 2004) . Oxidative stress in the liver after administration of phenobarbital or Metofluthrin was assessed by malondialdehyde as an indicator of lipid peroxidation, as well as total glutathione (GSH þ GSSG) and reduced glutathione as a measure of antioxidant capacity. However, no evidence was obtained for the involvement of oxidative stress in phenobarbital or Metofluthrin-induced rat liver tumor formation (Deguch et al., in press). Oxidative stress was not identified as a key event for liver tumor formation by phenobarbital and other CAR activators (Holsapple et al., 2006) .
Unlike oxidative stress, inhibition of apoptosis is considered a key event in the MOA for phenobarbital-induced rat liver tumors (Holsapple et al., 2006 ). An apoptosis marker (cytoplasmic histone-associated DNA-fragments level) was not markedly changed with Metofluthrin or phenobarbital treatment in our studies (Deguch et al., in press ). The method employed for determining apoptosis lacked the sensitivity of morphological procedures. Indeed, in this study, inhibition of apoptosis was only observed in male and not in female rats given phenobarbital (Deguch et al., in press). Hence, without additional studies we do not wish to draw any conclusions about any effects on apoptosis in support of a phenobarbitallike MOA for Metofluthrin.
In keeping with phenobarbital and related compounds (i.e., non-DNA-reactive carcinogens in general) (Whysner et al., 1996) , the effects of Metofluthrin were reversible on cessation of treatment (Deguch et al., in press).
Dose-Response Relationship
All of the parameters described above were evaluated with respect to dose, utilizing doses used in the 2-year bioassay (200, 900, or 1800 ppm) as well as an evaluation at a much higher level of 3600 ppm (consequently this dose level was extremely toxic) in both males and females (Table 2) .
Enzyme induction. CYP2B1/2 mRNA was induced greater than two-fold at doses of 900, 1800, and 3600 ppm (Table 2 ). In the general toxicity studies, hepatocellular hypertrophy, which indicated occurrence of enzyme induction, was observed at the bioassay dose levels of 900 and 1800 ppm and above.
Cell proliferation. Significant increases in the BrdUlabeling indices were noted at 900 and 1800 ppm in males ( Table 2 ). Owing to high values in the control group significant increases in the BrdU-labeling index were not observed in female rats. However, compared to the BrdU-labeling index value of the female 200 ppm Metofluthrin group (i.e., value expressed as 1.0), the labeling index values of the 900, 1800, and 3600 ppm were 1.2-, 2.1-, and 1.9-fold, respectively (Table 2 ).
Tumor induction. The incidence of hepatocellular adenomas and/or carcinomas was significantly increased in male rats given 900 and 1800 ppm Metofluthrin and in female rats given 1800 ppm Metofluthrin. The various parameters described above that are related to the key events in Metofluthrin-induced liver tumors were observed at or below the tumorigenic dose levels in males and females (Table 2) .
Taken together, there are strong parallels in the dose response for the key events and the tumor response. Again, it is noteworthy that the degree of changes observed in each of the parameters was relatively mild, consistent with the slight increase in tumor incidences, particularly when compared not only to the current controls but to the range of historical controls.
Temporal Association
It is critical in the evaluation of MOA that early key events occur before the appearance of tumors, and this is clearly the case with Metofluthrin. Increased enzyme induction and BrdUlabeling index were observed after as little as one week of dosing (Deguch et al., in press ). In addition, the increased BrdU-labeling indices returned to the control values during 2 weeks of dosing (Deguch et al., in press). The development of altered hepatic foci is also a key event in the MOA for phenobarbital-induced liver tumors (Holsapple et al., 2006) . Like phenobarbital, the appearance of such foci, adenomas and carcinomas occurred only after chronic administration of Metofluthrin. Metofluthrin produced liver foci at higher doses in common with the appearance of liver adenomas and carcinomas (Deguch et al., in press).
Strength, Consistency, and Specificity of Association of Key Events and Tumor Response
The early key events and preneoplastic changes were observed in the liver consistently at several time points before the actual appearance of neoplasms. Increased liver weight and hepatocellular hypertrophy were shown to appear in short-term 62 YAMADA ET AL.
(1 and 2 weeks), subacute (4 and 13 weeks), and chronic (26 and 52 weeks) studies. The increased amount of smooth endoplasmic reticulum was also observed after 1, 2, 4, and 26 weeks of treatment. The relationship of these changes to treatment with Metofluthrin was also well documented in the recovery study, showing that there was complete reversibility of all of these parameters when Metofluthrin treatment was discontinued (Deguch et al., in press).
While some species differences in CYP2B induction are known (Pustylnyak et al., 2007) , enzyme inducers such as phenobarbital normally induce CYP2B isoforms in both the rat and mouse. Recent short term studies in mice with Metofluthrin showed an effect on liver morphology and/or enzyme activity at dose levels of 1000 ppm and higher, as evidenced by increases of liver weights, centrilobular hepatocellular hypertrophy and increased CYP2B activity (Deguch, unpublished data). These finding are consistent with existing data, that is, increased liver weight and centrilobular hepatocellular hypertrophy observed in mice treated with Metofluthrin for 3 months and 1.5 years. However, bioassay dose levels of Metofluthrin induced no hepatic altered foci or tumors in mice.
Another feature of some CYP enzyme inducers in rats are the effects on the thyroid due to increased catabolism of thyroid hormones (thyroxine, T4; and triiodothyronine, T3), leading to increased thyroid stimulating hormone (TSH) and resulting thyroid hypertrophy, hyperplasia and tumors (Capen, 2001; Dellarco et al., 2006) . Metofluthrin-treatment revealed an increase in serum TSH levels (900 ppm and higher in males, 1800 ppm and higher in females) and increases in hepatic UGT activities toward T3 (1800 and higher in females) and T4 (1800 pm and higher in both sexes) (unpublished data). These findings were also observed for phenobarbital (unpublished data). Hepatic CYP2B and UGT were both induced by phenobarbital via CAR (Holsapple et al., 2006; Qatanani et al., 2005; Ueda et al., 2002; Wei et al., 2000; Yamamoto et al., 2004; Yoshinari et al., 2001) . Therefore, these effects of Metofluthrin on mouse liver and rat thyroid are also considered to occur via CAR, as for phenobarbital. However, the effects observed following Metofluthrin were much less potent than for phenobarbital (Deguch et al., in press; unpublished data), suggesting that this is the reason why Metofluthrin did not induce liver tumors in mice or thyroid tumors in rats. Indeed, in the rat studies with a series of barbiturates including phenobarbital some correlation was observed between the magnitude of CYP2B induction and liver tumor promoting activity (Lubet et al., 1989; Rice et al., 1994) . Therefore, the potency of enzyme induction by Metofluthrin may not be enough to induce cell proliferation in mouse liver and rat thyroid at dose levels examined in the bioassays.
Biological Plausibility and Coherence
The liver is by far the most common target tissue affected in cancer bioassays (Gold et al., 2001) . This may be due to the fact that the liver is the major site of metabolic activation of chemicals, and, furthermore, the liver is the first organ exposed to the chemical following absorption from the gastrointestinal tract (if administered orally, as in the case of the bioassays utilizing Metofluthrin). In addition, there is a relatively high background incidence of liver tumors in several strains of mice and rats. The background incidences in the strain of rats used in the studies with Metofluthrin at the laboratory where the studies were performed were 0-6% for males and 1-12% for females.
Several MOAs have been identified for the induction of liver tumors in rodents (Holsapple et al., 2006) , including DNA reactivity, cytotoxicity, and consequent regenerative proliferation, peroxisome proliferation, estrogen stimulation, and cytochrome P450 induction.
The MOA for liver tumor formation by phenobarbital which involves activation of CAR and CYP2B induction is well established (Holsapple et al., 2006; Whysner et al., 1996) . This is associated with increased liver weight, hepatocellular hypertrophy (especially in the centrilobular region), proliferation of smooth endoplasmic reticulum, and stimulation of cell replication as evidenced by labeling indices such as BrdU. Phenobarbital and related compounds are also known promoters of liver cell foci once formed. CYP2B induction has been shown to be associated with liver tumor formation in rodents for phenobarbital and related compounds (Holsapple et al., 2006; Whysner et al., 1996) and involves activation of nuclear receptors, particularly CAR (Ueda et al., 2002; Wei et al., 2000; Yamamoto et al., 2004; Yoshinari et al., 2001 ). While it is uncertain if CYP2B induction is a surrogate for a wider pleiotropic response (Ueda et al., 2002) or if CYP2B isoforms themselves play a role, for example by generating reactive oxygen species (Holsapple et al., 2006) , there is clear evidence from studies in knockout mice that CAR plays an essential role in phenobarbital-induced liver tumor formation (Yamamoto et al., 2004) . As described above, CAR dependency of Metofluthrin-induced CYP2B induction was confirmed in rat hepatocytes (Deguch et al., in press). The Metofluthrin-induced key events summarized above are similar to those seen with phenobarbital, and we can therefore conclude that Metofluthrin has a similar MOA to that of phenobarbital for rat liver tumor formation.
Other Modes of Action
As described above, there is strong evidence in support of CYP2B enzyme induction as the critical MOA for Metofluthrin. Other known MOAs for rodent liver carcinogenesis can be assessed from the data available from the various studies performed with Metofluthrin. Metofluthrin is clearly not genotoxic, being negative in a variety of in vivo and in vitro genotoxicity assays (Ames test, micronucleus test, and in vitro chromosomal aberration test). In the general toxicity studies, utilizing histopathology and electron microscopy techniques, there was no evidence of hepatocellular cytotoxicity (necrosis), CASE STUDY-METOFLUTHRIN peroxisome proliferation, or any evidence of hormone perturbations. Thus, it is highly likely that the MOA for Metofluthrin-induced liver tumors in rats is through a cytochrome P450 induction, similar to that seen for phenobarbital, and not via some other MOA.
Assessment of Postulated MOA
As described above, the key events in the MOA for Metofluthrin have been well documented, with a strong dose response and temporal consistency. In addition, this is a wellknown MOA, and the various parameters essential for documenting this MOA have been presented for Metofluthrin. Thus, we consider that the level of confidence in the postulated MOA is high.
Uncertainties, Inconsistencies, and Data Gaps
The CAR dependency for the stimulation of cell proliferation by Metofluthrin has not been established. However, we do not believe that this evaluation is essential and we consider that this data gap does not alter the overall postulated MOA for Metofluthrin-induced rat liver tumors. The remaining data gaps, thus, are not critical for the conclusion that liver tumors induced by Metofluthrin in the rat occur by the postulated cytochrome P450 induction MOA similar to that shown for phenobarbital.
For the most part, the data are quite consistent at several time points and at several doses. As noted in Table 2 , however, there are some apparent inconsistencies. Most critically, there is not an increase in BrdU-labeling index at the highest dose tested (3600 ppm) in either males or females (Table 2 ). This dose was not evaluated in the 2-year bioassay since it appears to be over the MTD. It is likely that there was no effect on the proliferation index in this study with Metofluthrin because of extremely high toxicity to the animals; in fact, animal death and tremor were observed at 3600 ppm ( Table 2 ). The positive effects were observed at the bioassay dose levels of 900 and 1800 ppm (Table 2 ) and also 2700 ppm (at this dose level, there was neither death nor tremor as was seen at 3600 ppm; Deguch et al., in press). Owing to high values in the control group significant increases in the BrdU-labeling index were not observed in female rats (Table 2) . However, as mentioned above, compared to the BrdU-labeling index value of the female 200 ppm Metofluthrin group, the labeling index values of the 1800 and 3600 ppm were higher.
Also, some of the parameters are not increased in the males administered 900 ppm Metofluthrin, even though that dose was weakly tumorigenic in the 2-year bioassay (Table 2) . However, the parameters that were not increased significantly at this dose are those in one week study that are the least sensitive indicators of changes in the liver, such as liver enlargement or hepatocellular hypertrophy. This could be due to the weak tumorigenic activity of Metofluthrin (only 8 out of 50 animals [16%] had liver tumors in the 900 ppm males) and small size (five animals per dose per sex) of the MOA study. Importantly, there were changes in CYP2B induction and in the BrdUlabeling index in this and at the higher dose of 1800 ppm, these being the most specific measures of the postulated key events.
ARE KEY EVENTS IN THE ANIMAL MOA PLAUSIBLE IN HUMANS?
Examination of the relevance of the MOA to humans requires not only information regarding the chemical of concern, but also an evaluation of the MOA (Cohen et al., 2004; Meek et al., 2003) . The first chemicals evaluated for a specific MOA will have a much higher requirement of data to prove the relevance or nonrelevance of the MOA than will subsequent chemicals. Thus, in this examination of Metofluthrin with regard to human relevance of the animal data, reliance can also be made on the evaluation of the MOA for similarly acting compounds, and in this case, the best example is phenobarbital. Phenobarbital has been identified as having a MOA involving CAR activation which results in the induction of CYP2B isoforms, an increase in cell proliferation and ultimately the development of liver tumors in rodents (Holsapple et al., 2006; Ueda et al., 2002; Wei et al., 2000; Whysner et al., 1996; Yamamoto et al., 2004; Yoshinari et al., 2001 ). As described above, the data strongly support a similar MOA for Metofluthrin.
In analyzing the relevance of the animal MOA data to humans, a concordance table has been suggested as being of considerable value (Meek et al., 2003) . This includes not only the data from Metofluthrin in the rat, but also a similar listing for the mouse and for the likely findings in human (Table 3) .
As described above, the sequence of key events in the rat is the induction of CYP2B enzyme, an increase in hepatocellular proliferation and ultimately the formation of a low incidence of hepatocellular adenomas and carcinomas. This occurs in both the male and female rat, with the male rat being slightly more sensitive. In contrast, there is induction of the cytochrome P450 enzymes in the mouse but there is no consequent increase in hepatocellular proliferation (as evidenced by lack of increased hepatocellular hyperplasia), and there is no increase in hepatocellular tumors, either adenomas or carcinomas, in either the male or the female mouse (unpublished data). The potency of CYP2B induction by Metofluthrin at dose levels used in the mouse bioassay is not be enough to induce cell proliferation and consequently no increase in liver tumors, however, the possibility of tumor appearance at higher dose levels of Metofluthrin (which could not be examined for carcinogenicity because of animal deaths resulting from neurotoxicity) cannot be ruled out. Phenobarbital is a more potent cytochrome P450 inducer than Metofluthrin and the tumor promoting effects of phenobarbital have been observed in both rats and mice (IARC, 2001; Whysner et al., 1996) .
In humans, we do not have any direct evidence for the effects of Metofluthrin. It is unlikely that such data will become 64 YAMADA ET AL.
available, but data derived from in vitro studies on human hepatocytes can be contributory and of value. Such data has been obtained using an in vitro comparison of human hepatocytes to rat hepatocytes treated with Metofluthrin or phenobarbital. Metofluthrin slightly induced CYP2B enzyme in rat and human hepatocytes as well as phenobarbital (but phenobarbital appeared to have a more marked effect) . The CYP2B induction with Metofluthrin in rat and human are similar to those observed with pyrethrins (Price et al., 2008) . Although CAR is expressed in humans, and phenobarbital induces CYP enzymes in human liver, phenobarbital apparently can act through other receptors as well, such as pregnane X receptor (Moore et al., 2003) . In addition, human CAR has been suggested as being activated by phenobarbital leading to not only activation of the CYP2B enzyme, but also in the induction of non-P450 genes, such as UGT1A1 (Sugatani et al., 2001) . The levels of exposure to phenobarbital in humans from therapeutic uses are comparable to serum levels achieved in animals that produce tumorigenic effects. Based on these analyses, the first key event, induction of CYP isoforms (CYP3A as well as CYP2B), occurs in humans at the levels of exposure that humans attain (Pirttiaho et al., 1982) . Based on the in vitro results and the rat in vivo studies at different exposure levels, induction of human hepatocytes is considerably less for Metofluthrin than phenobarbital at identical concentrations.
A more critical step is the effect on hepatocellular proliferation. It has been thought that there is an increase in liver size in humans after prolonged treatment with phenobarbital, and that the increased liver size in humans produced by phenobarbital appears to be due to hepatocellular hypertrophy (Holsapple et al., 2006) . Thus, there appears to be the same proliferation of smooth endoplasmic reticulum in human liver in response to phenobarbital that is seen in the rat and the mouse. However, limited studies with human hepatocytes in vitro suggest that the hepatocytes are refractory to the increased proliferative and anti-apoptotic effects of phenobarbital that occur in rodents (Hasmall and Roberts, 1999; Parzefall et al., 1991) . In our study, dose-dependent increase of DNA synthesis was detected in rat hepatocytes , which is consistent with previous findings (Hasmall and Roberts, 1999; Parzefall et al., 1991) , while various concentrations of phenobarbital had no effect on DNA synthesis associated with cell proliferation in human . Thus, there is significant evidence that this key event in phenobarbital-induced liver tumors in rodents, increased cell proliferation, does not occur in the human liver. Most importantly, there is also substantial epidemiological evidence for the non-carcinogenicity of phenobarbital in humans (IARC, 2001; Olsen et al., 1989 Olsen et al., , 1995 Whysner et al., 1996) . Again, the exposure levels in humans are similar to those in rodents, and also, administration to humans occurs over a period of many years, frequently beginning in childhood and continuing for essentially the lifetime of the individual. Such studies have demonstrated that in human subjects receiving phenobarbital for many years at doses producing plasma concentrations similar to those which are carcinogenic in rodents there is no evidence of increased liver tumor risk. As phenobarbital, human hepatocyte was also refractory to the increased hepatocellular proliferation by methofluthrin that occur in rodents . Similar to phenobarbital it is not expected to produce an increase in hepatocellular proliferation, and therefore, would not result in an increase in liver tumors. Based on this analysis, the answer to the question regarding plausibility in humans is likely to be ''no'' for Metofluthrin (Fig. 2) .
TAKING INTO ACCOUNT KINETIC AND DYNAMIC FACTORS, IS THE ANIMAL MOA PLAUSIBLE IN HUMANS?
Continuing the analogy with phenobarbital, Metofluthrin quantitatively would also not be expected to induce cancer in humans. In contrast to phenobarbital exposures in humans, Metofluthrin is expected to have exposures considerably lower in humans than those that were used for the animal studies. For both phenobarbital and Metofluthrin in the animal studies, the effects on the liver occur only at high doses. This is characteristic for most MOA involving non-DNA-reactive agents indicating the presence of a threshold (Cohen and Ellwein, 1990 Ellwein, , 1991 . For phenobarbital, however, this high level of exposure occurs not only in the animal, but also in humans. Metofluthrin produced hepatocellular changes also only at extremely high exposure levels, 900 ppm in the male rat (38.08 mg/kg/day) and 1800 ppm in the female rat (96.13 mg/ kg/day), but in contrast to phenobarbital, these levels are considerably higher than what would be expected for human exposure (0.000996 mg/kg/day for adult; 0.00055 mg/kg/day for child). Thus, not only is there a qualitative difference between the rodent and human in the response of the liver cells to the cytochrome P450 inducers regarding induction of tumors, but also a marked quantitative difference in the level of exposure. Thus, based on quantitative considerations, the confidence in a lack of effect in humans at expected exposures is even stronger than that based only on qualitative consideration (Fig. 2) . It has also been strongly suggested that possible susceptible populations and life stages be considered in the overall evaluation. There does not appear to be any susceptible subpopulation regarding cytochrome P450 induction, other than a decreased level rather than an increased level in certain individuals with polymorphisms potentially leading to a decrease in activity. However, this would only decrease expected responses rather than increase susceptibility. Similarly, there is no data to suggest that exposure early in life is likely to result in a greater response than later in life. There was no evidence of liver toxicity in the reproductive and developmental toxicology studies with Metofluthrin. Carcinogenicity was not evaluated for the neonatal life stage for Metofluthrin, but phenobarbital was evaluated in the neonatal mouse model without evidence of a tumorigenic effect (McClain et al., 2001 ). Furthermore, if there is a difference, cytochrome P450 induction appears to be less at young ages compared to adult ages in humans as well as in animals (Sipes and Gandolfi, 1986) . Thus, if any effect, the infant life stage and young life stage would be expected to be less susceptible to the effects of such agents than would be the adult. Thus, specific susceptible populations, including life stages, are not expected.
STATEMENT OF CONFIDENCE, ANALYSIS, AND IMPLICATIONS
Based on the above presentation, there is strong evidence to support a MOA of Metofluthrin-induced hepatocellular tumors in male and female rats involving CYP2B induction through CAR activation, an increase in hepatocellular proliferation and ultimately a slight increase in liver tumors. This MOA is similar to that demonstrated for phenobarbital, a chemical for which there is strong epidemiological data supporting noncarcinogenicity in humans. The data strongly support the conclusion that qualitatively this MOA would not occur in humans following exposure to Metofluthrin, similar to the conclusion with phenobarbital. In addition, unlike phenobarbital, the levels of exposure to Metofluthrin in the rat are considerably higher than are anticipated to occur in humans. In the rat, there is strong evidence for a threshold response, as would be expected for this MOA. Thus, qualitatively the MOA is not relevant to humans.
The data available for Metofluthrin are considerable, and, despite some data gaps, such as the lack of available data regarding CAR involvement in increasing cell proliferation following Metofluthrin exposure, the MOA for Metofluthrininduced rat liver tumors is by CYP2B induction and increased cell proliferation. Based on the evidence, including a comparison with the results with another chemical, phenobarbital, acting by a similar MOA, it is reasonable to conclude that Metofluthrin will not have any hepatocarcinogenic activity in humans.
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